Safety and efficacy of different doses of anthracyclines combined with arsenic trioxide and all-trans retinoic acid in the treatment of de novo acute promyelocytic leukemia

CONCLUSION: Low-dose group achieves outcomes similar to those of standard dose group for APL patients, but the low-dose group may be even safer than standard-dose group. So the low-dose anthracycline may be a better choice for newly diagnosed APL patients.PMID:33631089 | DOI:10.1080/16078454.2021.1889159

Source: Hematology - February 25, 2021 Category: Hematology Authors: Yaxue Wu Peng Ke Haixia Zhou Depei Wu Suning Chen Huiying Qiu Yue Han Caixia Li Xiao Ma Aining Sun Xiaowen Tang Xiaohui Hu Source Type: research